NASDAQ:VKTX - Viking Therapeutics Stock Price, Price Target & More

$4.71 +0.16 (+3.52 %)
(As of 04/22/2018 06:59 AM ET)
Previous Close$4.71
Today's Range$4.53 - $4.8550
52-Week Range$0.88 - $7.36
Volume934,483 shs
Average Volume774,619 shs
Market Capitalization$231.75 million
P/E Ratio-5.96
Dividend YieldN/A
Beta2.09

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Debt-to-Equity RatioN/A
Current Ratio2.53%
Quick Ratio2.53%

Price-To-Earnings

Trailing P/E Ratio-5.96
Forward P/E Ratio-10.70
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book12.39

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-276.21%
Return on Assets-129.79%

Miscellaneous

Employees14
Outstanding Shares50,930,000

How to Become a New Pot Stock Millionaire

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics (NASDAQ:VKTX) released its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.04. View Viking Therapeutics' Earnings History.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Viking Therapeutics.

What price target have analysts set for VKTX?

3 Wall Street analysts have issued 12 month target prices for Viking Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they expect Viking Therapeutics' stock price to reach $9.00 in the next year. View Analyst Ratings for Viking Therapeutics.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 52)
  • Mr. Michael Morneau, CFO & Principal Accounting Officer (Age 53)
  • Mr. Gregory S. Zante CPA, VP of Fin. & Operations (Age 47)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Dr. Hiroko Masamune Ph.D., Sr. VP of Pharmaceutical Devel. (Age 61)

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Has Viking Therapeutics been receiving favorable news coverage?

Press coverage about VKTX stock has trended positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.25 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.45 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $4.71.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $231.75 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (VKTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Viking Therapeutics (NASDAQ:VKTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Viking Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 91.08%. The high price target for VKTX is $11.00 and the low price target for VKTX is $8.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$7.6667$7.00$6.00
Price Target Upside: 91.08% upside36.18% upside76.32% upside217.46% upside

Viking Therapeutics (NASDAQ:VKTX) Consensus Price Target History

Price Target History for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018HC WainwrightReiterated RatingBuy -> Buy$11.00HighView Rating Details
3/8/2018Roth CapitalSet Price TargetBuy$8.00HighView Rating Details
3/8/2018Maxim GroupReiterated RatingBuy$8.00HighView Rating Details
8/11/2016LaidlawLower Price TargetBuy$20.00 -> $10.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Viking Therapeutics (NASDAQ:VKTX) Earnings History and Estimates Chart

Earnings by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.44 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS

Viking Therapeutics (NASDAQ VKTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.15)N/AView Earnings Details
3/7/2018Q4 2017($0.18)($0.14)ViewListenView Earnings Details
11/8/2017Q3 2017($0.19)($0.22)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.21)ViewListenView Earnings Details
5/10/2017Q1 2017($0.17)($0.23)ViewN/AView Earnings Details
3/21/2017Q4 2016($0.20)($0.18)ViewN/AView Earnings Details
11/10/2016Q316($0.21)($0.20)ViewN/AView Earnings Details
8/10/2016Q2($0.20)($0.22)ViewN/AView Earnings Details
5/10/2016Q1($0.45)($0.40)ViewN/AView Earnings Details
3/8/2016Q415($0.44)($0.56)ViewN/AView Earnings Details
11/5/2015($0.37)($0.53)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($1.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Viking Therapeutics (NASDAQ:VKTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 18.34%
Insider Trading History for Viking Therapeutics (NASDAQ:VKTX)
Insider Trading History for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ VKTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2016Matthew W FoehrDirectorBuy13,000$1.21$15,730.0039,250View SEC Filing  
4/13/2016Matthew W FoehrDirectorBuy20,000$1.24$24,800.0026,250View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Viking Therapeutics (NASDAQ VKTX) News Headlines

Source:
DateHeadline
HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (VKTX)HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (VKTX)
www.americanbankingnews.com - April 17 at 11:58 PM
Viking Therapeutics (VKTX) Downgraded by ValuEngineViking Therapeutics (VKTX) Downgraded by ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM
What Should Investors Know About Viking Therapeutics Inc’s (NASDAQ:VKTX) Future?What Should Investors Know About Viking Therapeutics Inc’s (NASDAQ:VKTX) Future?
finance.yahoo.com - April 13 at 5:31 PM
Viking Therapeutics (VKTX) Upgraded to Buy at ValuEngineViking Therapeutics (VKTX) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM
Why Viking Therapeutics, Inc. Stock Cratered in MarchWhy Viking Therapeutics, Inc. Stock Cratered in March
finance.yahoo.com - April 12 at 8:39 AM
Viking Therapeutics (VKTX) Given a $5.00 Price Target at Maxim GroupViking Therapeutics (VKTX) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - April 10 at 11:38 PM
Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.11 Per ShareViking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 7 at 5:22 PM
Viking Therapeutics (VKTX) Stock Rating Upgraded by ValuEngineViking Therapeutics (VKTX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM
HC Wainwright Analysts Give Viking Therapeutics (VKTX) a $11.00 Price TargetHC Wainwright Analysts Give Viking Therapeutics (VKTX) a $11.00 Price Target
www.americanbankingnews.com - March 26 at 8:36 AM
Viking Therapeutics (VKTX) Downgraded to "Hold" at BidaskClubViking Therapeutics (VKTX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 16 at 10:28 PM
VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020
finance.yahoo.com - March 9 at 6:49 PM
Heres Why Viking Therapeutics Stock Dropped as Much as 17.3% Today - Motley FoolHere's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today - Motley Fool
www.fool.com - March 9 at 8:21 AM
Viking Therapeutics (VKTX) Stock Rating Reaffirmed by Maxim GroupViking Therapeutics (VKTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - March 8 at 9:58 PM
Roth Capital Analysts Give Viking Therapeutics (VKTX) a $8.00 Price TargetRoth Capital Analysts Give Viking Therapeutics (VKTX) a $8.00 Price Target
www.americanbankingnews.com - March 8 at 7:43 PM
Streetwise newsletter: Raging River’s search for relevance, RBC’s gender diversity ETFsStreetwise newsletter: Raging River’s search for relevance, RBC’s gender diversity ETFs
www.theglobeandmail.com - March 8 at 6:41 PM
Heres Why Viking Therapeutics Dropped as Much as 17.3% TodayHere's Why Viking Therapeutics Dropped as Much as 17.3% Today
www.msn.com - March 8 at 6:41 PM
Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% TodayHere's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today
finance.yahoo.com - March 8 at 6:41 PM
Viking Therapeutics (VKTX) Posts  Earnings Results, Beats Estimates By $0.04 EPSViking Therapeutics (VKTX) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 8 at 9:04 AM
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 ... - PR Newswire (press release)Viking Therapeutics Reports Fourth Quarter and Year-End 2017 ... - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:24 AM
Viking Therapeutics (VKTX) CEO Brian Lian on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaViking Therapeutics' (VKTX) CEO Brian Lian on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 8:24 AM
Viking Therapeutics, Inc. to Host Earnings CallViking Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate UpdateViking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 6:33 PM
Viking Therapeutics to Present at Upcoming Investor Conferences - PR Newswire (press release)Viking Therapeutics to Present at Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:16 AM
Viking Therapeutics to Present at Upcoming Investor ConferencesViking Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 8:16 AM
Viking Therapeutics (VKTX) Scheduled to Post Earnings on WednesdayViking Therapeutics (VKTX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - March 1 at 8:14 PM
EAM Investors LLC Takes $2.54 Million Position in Viking Therapeutics Inc (VKTX)EAM Investors LLC Takes $2.54 Million Position in Viking Therapeutics Inc (VKTX)
www.americanbankingnews.com - February 28 at 2:14 PM
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
finance.yahoo.com - February 28 at 8:18 AM
Acceleron Pharma (XLRN) versus Viking Therapeutics (VKTX) Head-To-Head AnalysisAcceleron Pharma (XLRN) versus Viking Therapeutics (VKTX) Head-To-Head Analysis
www.americanbankingnews.com - February 17 at 11:18 PM
Zacks: Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPSZacks: Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce -$0.19 EPS
www.americanbankingnews.com - February 15 at 9:12 PM
Viking Therapeutics (VKTX) Rating Lowered to Buy at BidaskClubViking Therapeutics (VKTX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - February 15 at 11:18 AM
Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)?Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)?
finance.yahoo.com - February 9 at 9:53 AM
Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs?Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs?
finance.yahoo.com - February 8 at 8:12 AM
Viking Therapeutics (VKTX) Upgraded at BidaskClubViking Therapeutics (VKTX) Upgraded at BidaskClub
www.americanbankingnews.com - February 7 at 11:30 AM
Viking Therapeutics to Present at 2018 BIO CEO & Investor ConferenceViking Therapeutics to Present at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:41 AM
Zacks: Viking Therapeutics Inc (VKTX) Given $8.38 Average Target Price by AnalystsZacks: Viking Therapeutics Inc (VKTX) Given $8.38 Average Target Price by Analysts
www.americanbankingnews.com - February 2 at 5:12 PM
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common StockViking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
finance.yahoo.com - February 2 at 9:31 AM
Should You Be Concerned About Viking Therapeutics Inc’s (NASDAQ:VKTX) Risks?Should You Be Concerned About Viking Therapeutics Inc’s (NASDAQ:VKTX) Risks?
finance.yahoo.com - February 1 at 3:43 PM
Biotech Viking Therapeutics Could Double From Here -- But Not Without RiskBiotech Viking Therapeutics Could Double From Here -- But Not Without Risk
finance.yahoo.com - January 30 at 3:44 PM
Viking Therapeutics Inc (VKTX) Short Interest Up 48.1% in JanuaryViking Therapeutics Inc (VKTX) Short Interest Up 48.1% in January
www.americanbankingnews.com - January 28 at 1:06 AM
VKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 TrialVKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 Trial
finance.yahoo.com - January 24 at 3:52 PM
Critical Contrast: Viking Therapeutics (VKTX) versus Arrowhead Pharmaceuticals (ARWR)Critical Contrast: Viking Therapeutics (VKTX) versus Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - January 18 at 1:32 PM
Vikings VK2809: A Question Of Safety, Not Efficacy - Seeking AlphaViking's VK2809: A Question Of Safety, Not Efficacy - Seeking Alpha
seekingalpha.com - January 10 at 4:24 PM
Viking Therapeutics to Present at Biotech Showcase 2018Viking Therapeutics to Present at Biotech Showcase 2018
www.prnewswire.com - January 2 at 7:53 AM
What Should We Expect From Viking Therapeutics Inc’s (NASDAQ:VKTX) Earnings Over The Next Few Years?What Should We Expect From Viking Therapeutics Inc’s (NASDAQ:VKTX) Earnings Over The Next Few Years?
finance.yahoo.com - December 30 at 10:13 AM
Zacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 30 at 7:46 AM
Viking Therapeutics: Expecting Further Upside In 2018 - Seeking AlphaViking Therapeutics: Expecting Further Upside In 2018 - Seeking Alpha
seekingalpha.com - December 13 at 10:54 AM
Maxim Group Analysts Give Viking Therapeutics (VKTX) a $8.00 Price TargetMaxim Group Analysts Give Viking Therapeutics (VKTX) a $8.00 Price Target
www.americanbankingnews.com - December 12 at 3:16 PM
Viking Therapeutics Announces Closing of Public Offering of Common StockViking Therapeutics Announces Closing of Public Offering of Common Stock
finance.yahoo.com - December 11 at 4:33 PM
 Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - December 9 at 9:08 PM
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/ShViking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh
www.streetinsider.com - December 7 at 4:39 PM

SEC Filings

Viking Therapeutics (NASDAQ:VKTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Viking Therapeutics (NASDAQ VKTX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.